Diabetes, Obesity and Metabolism, 1462-8902

Tidskrift

Fler filtreringsmöjligheter
  1. 2019
  2. Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: A nested, case–control study

    The SUMMIT consortium, Natali, A., Nesti, L., Venturi, E., Shore, A. C., Khan, F., Gooding, K., Gates, P. E., Looker, H. C., Dove, F., Isabel Goncalves, Margaretha Persson & Jan Nilsson, 2019 feb, I : Diabetes, Obesity and Metabolism. 21, 2, s. 412-416

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  3. 2018
  4. MicroRNAs in islet hormone secretion

    Jonathan L.S. Esguerra, Mototsugu Nagao, Jones K. Ofori, Anna Wendt & Lena Eliasson, 2018 sep 1, I : Diabetes, Obesity and Metabolism. 20, Suppl 2, s. 11-19

    Forskningsoutput: TidskriftsbidragÖversiktsartikel

  5. Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

    Bo Ahrén, Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., Holst, A. G. & Leiter, L. A., 2018 sep 1, I : Diabetes, Obesity and Metabolism. 20, 9, s. 2210-2219 10 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  6. Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients

    Alsalim, W., Margaretha Persson & Bo Ahrén, 2018 jul, I : Diabetes, Obesity and Metabolism. 20, 7, s. 1652-1658

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  7. Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects

    Alsalim, W., Olga Göransson, Carr, R. D., Bizzotto, R., Tura, A., Pacini, G., Mari, A. & Bo Ahrén, 2018 apr, I : Diabetes, Obesity and Metabolism. 20, 4, s. 1080-1085

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  8. 2017
  9. Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial

    Yabe, D., Eto, T., Shiramoto, M., Irie, S., Murotani, K., Seino, Y., Kuwata, H., Kurose, T., Seino, S., Bo Ahrén & Seino, Y., 2017, I : Diabetes, Obesity and Metabolism. 19, 3, s. 442-447

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  10. Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes

    Preiss, D., Dawed, A., Welsh, P., Heggie, A., Jones, A. G., Dekker, J., Robert Koivula, Hansen, T. H., Stewart, C., Holman, R. R., Paul W. Franks, Walker, M., Pearson, E. R. & Sattar, N., 2017, I : Diabetes, Obesity and Metabolism. 19, 3, s. 356-363

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  11. 2016
  12. Mixed meal diminishes glucose excursion compared to glucose by several adaptive mechanisms in man.

    Alsalim, W., Tura, A., Pacini, G., Omar, B., Bizzotto, R., Mari, A. & Bo Ahrén, 2016, I : Diabetes, Obesity and Metabolism. 18, 1, s. 24-33

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  13. 2015
  14. The Islet and Metabolism Keep Time

    Thorens, B., Accili, D., Bo Ahrén, Cerasi, E., Seino, S. & Boitard, C., 2015, I : Diabetes, Obesity and Metabolism. 17, Suppl 1, s. 3-5

    Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

  15. 2014
  16. Pronounced Reduction Of Postprandial Glucagon By Lixisenatide: A Meta-Analysis Of Randomized Clinical Trials.

    Bo Ahrén, Gautier, J-F., Berria, R., Stager, W., Aronson, R. & Bailey, C. J., 2014, I : Diabetes, Obesity and Metabolism. 16, 9, s. 861-868

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  17. The mind and the belly: a glance at how the nervous system directs metabolism

    Accili, D., Bo Ahrén, Boitard, C., Seino, S., Thorens, B. & Cerasi, E., 2014, I : Diabetes, Obesity and Metabolism. 16, s. 1-3

    Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

  18. 2013
  19. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials

    Monami, M., Bo Ahrén, Dicembrini, I. & Mannucci, E., 2013, I : Diabetes, Obesity and Metabolism. 15, 2, s. 112-120

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  20. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects.

    Lena Ohlsson, Alsalim, W., Carr, R. D., Tura, A., Pacini, G., Mari, A. & Bo Ahrén, 2013, I : Diabetes, Obesity and Metabolism. 15, 6, s. 531-537

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  21. Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

    Nauck, M., Frid, A., Hermansen, K., Thomsen, A. B., During, M., Shah, N., Tankova, T., Mitha, I. & Matthews, D. R., 2013, I : Diabetes, Obesity and Metabolism. 15, 3, s. 204-212

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  22. Shifting the paradigm of islet inflammation-good guy or bad guy?

    Bo Ahrén, Accili, D., Boitard, C., Cerasi, E., Thorens, B. & Seino, S., 2013, I : Diabetes, Obesity and Metabolism. 15, s. 4-9

    Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

  23. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function

    Alba, M., Bo Ahrén, Inzucchi, S. E., Guan, Y., Mallick, M., Xu, L., O'Neill, E. A., Williams-Herman, D. E., Kaufman, K. D. & Goldstein, B. J., 2013, I : Diabetes, Obesity and Metabolism. 15, 12, s. 1101-1110

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  24. 2012
  25. The hyperstimulated beta-cell: prelude to diabetes?

    Boitard, C., Accili, D., Bo Ahrén, Cerasi, E., Seino, S. & Thorens, B., 2012, I : Diabetes, Obesity and Metabolism. 14, S3, s. iv-viii

    Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

  26. Using albumin to improve the therapeutic properties of diabetes treatments.

    Bo Ahrén & Burke, B., 2012, I : Diabetes, Obesity and Metabolism. 14, s. 121-129

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  27. 2011
  28. Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)

    Lindblad, U., Lindberg, G., Månsson, N-O., Jonas Ranstam, Tyrberg, M., Jansson, S., Lindwall, K., Svärdh, M., Kindmalm, L. & Melander, A., 2011, I : Diabetes, Obesity and Metabolism. 13, 2, s. 185-188

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  29. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.

    Bo Ahrén, Foley, J. E. & Bosi, E., 2011, I : Diabetes, Obesity and Metabolism. 13, 3, s. 193-203

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Föregående 1 2 3 Nästa